Response to neoadjuvant chemotherapy in ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary peritoneal carcinoma (EOC) treatment
Authors
Clamp, Andrew RMcNeish, I
Dean, A
Gallardo-Rincon, D
Kim, J
O'Donnell, D
Hook, J
Blagden, S
Brenton, J
Naik, R
Perren, T
Sundar, S
Cook, A
James, E
Gabra, H
Lord, R
Hall, M
Dark, G
Kaplan, R
Ledermann, J
Affiliation
Medical Oncology, The Christie NHS Foundation Trust, Manchester, UKIssue Date
2018
Metadata
Show full item recordCitation
Clamp AR, McNeish IA, Dean A, Gallardo-Rincon D, Kim JW, O�Donnell DM, et al. 943PD Response to neoadjuvant chemotherapy in ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment. Ann Oncol. 2018;29(suppl_8):336.Journal
Annals of OncologyDOI
10.1093/annonc/mdy285.151Additional Links
https://dx.doi.org/10.1093/annonc/mdy285.151Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdy285.151